Speaker Profile

Ph.D., Executive Vice President and Head of R&D, Lava Therapeutics

Prof. Paul W.H.I. Parren is dedicated to translating antibody biology and immunotherapy knowledge into innovative therapeutics and technologies. He holds a PhD in molecular immunology from the University of Amsterdam (1992). Prof. Parren was an Associate Professor at The Scripps Research Institute in La Jolla, California. From 2002-2017, he led research and preclinical development at Genmab, leading to seven product approvals to date. He is an inventor of ofatumumab (Arzerra, 2009; KESIMPTA, 2020), daratumumab (DARZALEX, 2015, DARZALEX-Faspro, 2021), teprotumumab (Tepezza, 2020), amivantamab (RYBREVANT, 2021), tisotumab vedotin (Tivdak, 2021) and two clinically translated technologies to generate bispecific (DuoBody) and effector-function enhanced (HexaBody) antibodies. In 2015, he became a Professor of Molecular Immunology at the Leiden University Medical Center in Leiden. In 2018, he joined LAVA Therapeutics, a biotechnology company focused on developing bispecific gamma-delta T cell engagers to transform cancer therapy, as its Executive Vice President and Head of R&D.

Bispecific Gamma-delta T Cell Engagers
LAVA is developing a bispecific antibody γδ T cell engager (bsTCEs) platform that leverages the unique qualities of γ9δ2 effector T cells. LAVA’s bsTCEs were selected to create a wide therapeutic window with high activity against tumor cells whilst leaving healthy cells unharmed. LAVA progressed two bsTCEs to the clinic, one in haematological cancer and one in oncology.

 Session Abstract – PMWC 2022 Silicon Valley

Track Chair:
Ira Mellman, Genentech

Human cells have been successfully used as treatment for blood cancers for decades but translating the promise to cell-based treatment for solid tumors has been slow. The advent of gene-editing techniques such as CRISPR, coupled with advances in our understanding of immunology and optimization of growing, manufacturing, transporting, storing, and handling specialized biological samples and materials is transforming the cell therapy field. We will hear in this session about some of the most promising work in the field, as well as the challenges in overcoming resistance

  • Recent Advances in Cell-based Therapy
    Session Chair: Ira Mellman, Genentech
    - Nicholas Haining, ArsenalBio
    - Elliot Norry, Adaptimmune
    - Sarah Cooley, Fate Therapeutics
    - Liz Homans, Lyell
  • Patentability of Immunotherapies - Latest Developments
    - Janet Xiao, Morrison & Foerster LLP
  • Cell-based Therapy Challenges
    Session Chair: Lawrence Corey, Fred Hutchinson Cancer Research Center
    - Sharon Benzeno, Adaptive Biotechnologies
    - Arati Rao, PACT Pharma
    - Mark Kotter, bit.bio
  • Next-generation Supply Chain For Cell & Gene Therapies
    Session Chair: Sharon Benzeno, Adaptive Biotechnologies
    - Amy DuRoss, Vineti
    - Tim Moore, Pact Pharma
    - Teresa Foy, BMS
  • Biomarkers to Guide Immunotherapy
    Session Chair: Danny Wells, ImmunAI
    - Sanjeev Mariathasan, Genentech
    - Christine Spencer, PICI
    - Klaus Lindpaintner, InterVenn Bioscience
  • Advances in Multi-Omic Spatial Profiling
    Session Chair: Sarah Warren, NanoString Technologies
    - Chris Corless, OHSU
  • Engineered Therapeutics
    Session Chair: Daniel Chen, SITC
    - Kole Roybal, UCSF
    - Paul Parren, Lava Therapeutics